Epidermolysis Bullosa Simplex Clinical Trial
Official title:
An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
Verified date | October 2019 |
Source | Castle Creek Pharmaceuticals, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.
Status | Terminated |
Enrollment | 54 |
Est. completion date | October 31, 2018 |
Est. primary completion date | October 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years and older |
Eligibility |
Key Inclusion Criteria: - Subject is at least 4 years of age at Screening - Subject has a documented genetic mutation consistent with EBS. Gene mutations acceptable for inclusion are as follows: KRT5, KRT14, PLEC1, TGM5, PKP1, DSP, FERMT1, EXPH5, DST, KLHL24. - Subject has an Assessment Area of EBS lesions to be treated, that is =2% body surface area (BSA) and the EBS lesions are in one or both of the following body areas: - Localized: plantar and/or palmar areas - Generalized: arms, legs, torso, hands and feet - Subject's EBS lesions in the Assessment Area have an Investigator's Global Assessment (IGA) score of =3 - Subject/caregiver agrees to not use any topical therapies other than the study medication that might influence the status of the EBS lesions during the duration of the study - Subject is non-pregnant as confirmed by a negative urine pregnancy screen, non-lactating and is not planning for pregnancy during the study period - If the subject is a woman of childbearing potential, agrees to use an approved effective method of birth control - Subject is in good general health and free of any known disease state or physical condition which might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation Key Exclusion Criteria: - Subject has EBS lesions to be treated that are infected - Subject has used any diacerein containing product within 6 months prior to Screening - Subject has used systemic immunotherapy or cytotoxic chemotherapy within 60 days prior to Screening - Subject has used systemic steroidal therapy or has used topical steroidal therapy on the EBS lesions to be treated within 30 days prior to Baseline - Subject has evidence of a systemic infection or has used systemic antibiotics within 7 days prior to Screening - Subject is currently using systemic analgesics and/or anti-histamine therapy, for treatment of EBS lesions unless on a stable regimen (i.e., the same dosing regimen) for at least 4 weeks prior to Screening - Subject has used any systemic diuretics or cardiac glycosides or any systemic product that might put the subject at undue risk - Subject has used any topical product containing allantoin on the EBS lesions to be treated within 30 days prior to Screening - Subject has a current malignancy, or a history of treatment for a malignancy within 2 years prior to Screening - Subject currently has diabetes mellitus (HbA1c =6.5%) or controlled diabetes (HbA1c < 6.5%) - Subject has a history of cardiac, hepatic (ALT and or AST >2x ULN, Total bilirubin >1.5x ULN at Screening), or renal disease (eGFR<30 ml/min/1.73 m^2) - Subject has a non-EBS skin disease or condition (e.g., sunburn) that might put the subject at undue risk by study participation or interferes with the study medication application or the study assessments |
Country | Name | City | State |
---|---|---|---|
Australia | Premier Specialists Pty Ltd; The Church | Kogarah | New South Wales |
Austria | EB House Austria | Salzburg | |
France | CHU de NICE - Hopital de l'Archet II - Service de Dermatologie | Nice | |
France | Hopital Necker-Enfants Malades | Paris | Cedex |
France | Hopital Saint Louis | Paris | Cedex |
Germany | University Medical Center Freiburg | Freiburg | |
Israel | Tel Aviv Sourasky Medical Center | Tel Aviv | |
Netherlands | University Medical Center Groningen | Groningen | |
United Kingdom | Great Ormond Street Hospital | London | England |
United Kingdom | St. Thomas' Hospital - St Johns Institute of Dermatology | London | |
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | University of North Carolina - Chapel Hill | Chapel Hill | North Carolina |
United States | Medical University of South Carolina (MUSC) | Charleston | South Carolina |
United States | Ann and Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Northwestern University | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | University of Missouri Healthcare | Columbia | Missouri |
United States | University of Minnesota | Minneapolis | Minnesota |
United States | Stanford University | Palo Alto | California |
United States | Phoenix Childrens Hospital | Phoenix | Arizona |
United States | Children's Hospital of San Antonio ; Texas Dermatology and Laser Specialists | San Antonio | Texas |
United States | Stony Brook University Medical Center | Stony Brook | New York |
Lead Sponsor | Collaborator |
---|---|
Castle Creek Pharmaceuticals, LLC |
United States, Australia, Austria, France, Germany, Israel, Netherlands, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Subjects Who Achieved = 60% Reduction in Body Surface Area (BSA) of EBS Lesions Within Assessment Area | Analysis of the proportion of subjects who achieved a =60% reduction in Body Surface Area (BSA) of EBS lesions within Assessment Area from Baseline to Week 8 | Baseline to Week 8 | |
Secondary | The Proportion of Subjects Who Achieved Success on the Investigator's Global Assessment (IGA) | The investigator's global assessment (IGA) is a five-point scale that is used for overall clinical assessment of severity of disease and classifies EBS-involved skin with a score ranging from 0-4. Success on the IGA was defined as =2-point reduction from Baseline to Visit 6 (Week 8). IGA Scoring: 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; 4 = Severe Minimum score = 0 Maximum score = 4; higher score = worse outcome |
Baseline to Week 8 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02592954 -
Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin
|
Phase 1 | |
Recruiting |
NCT03269474 -
Computational Drug Repurposing for All EBS Cases
|
||
Completed |
NCT05062070 -
Safety and Efficacy of Topical TolaSure Targeting Aggregated Mutant Keratin in Severe Epidermolysis Bullosa Simplex
|
Phase 1 | |
Recruiting |
NCT03016715 -
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
|
Phase 2 | |
Completed |
NCT02960997 -
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
|
Phase 2 | |
Recruiting |
NCT00936533 -
Botulinumtoxin A Treatment in Epidermolysis Bullosa Simplex and Pachyonychia Congenita
|
Phase 2 | |
Completed |
NCT03472287 -
To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)
|
Phase 1 | |
Recruiting |
NCT04213703 -
A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
|
||
Not yet recruiting |
NCT02470689 -
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
|
Phase 2 | |
Recruiting |
NCT03453632 -
Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05033574 -
The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
|
||
Completed |
NCT04908215 -
INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa
|
Phase 2 | |
Completed |
NCT03389308 -
Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex
|
Phase 2 |